000-19125
|
33-0336973
|
|
(Commission File No.)
|
(IRS Employer Identification No.)
|
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01.
|
Entry into a Material Definitive Agreement.
|
Item 2.03.
|
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
|
Item 9.01. | Financial Statements and Exhibits. |
(d)
|
Exhibits.
|
10.1
|
Amendment No.1 to Loan Documents between Ionis Pharmaceuticals, Inc. and Morgan Stanley Private Bank, National Association dated December 30, 2015.
|
Ionis Pharmaceuticals, Inc. | ||
Dated: January 5, 2016
|
By:
|
/s/ B. Lynne Parshall
|
B. Lynne Parshall
|
||
Chief Operating Officer
|
Amendment No.1 to Loan Documents between Ionis Pharmaceuticals, Inc. and Morgan Stanley Private Bank, National Association dated December 30, 2015.
|
(a)
|
Any and all references to “Borrower”, “Grantor” or “Isis Pharmaceuticals, Inc.” in the Loan Documents are hereby amended and restated as, and deemed to be references to, “Ionis Pharmaceuticals, Inc.”.
|
(a)
|
Section 5.03(a) of the Agreement is hereby amended and restated as follows:
|
(b)
|
Schedule 4.01(h) of the Agreement is hereby amended and replaced with Schedule 4.01(h) attached hereto as Exhibit A.
|
LENDER:
|
BORROWER:
|
||||
MORGAN STANLEY PRIVATE BANK, NATIONAL ASSOCIATION
|
IONIS PHARMACEUTICALS, INC.
|
||||
By: |
/s/Mark Reardon
|
By: |
/s/ Elizabeth L. Hougen
|
||
Name:
|
Mark Reardon
|
Name:
|
Elizabeth L. Hougen
|
||
Title:
|
Authorized Signatory
|
Title:
|
SVP Finance and CFO
|
Owner
|
Entity
|
Percentage
|
FMR LLC
|
Ionis Pharmaceuticals, Inc.
|
14.8%(1)
|
ClearBridge Investments, LLC
|
Ionis Pharmaceuticals, Inc.
|
7.4%(1)
|
Baillie Gifford & Co.
|
Ionis Pharmaceuticals, Inc.
|
7.4%(1)
|
The Vanguard Group
|
Ionis Pharmaceuticals, Inc.
|
7.3%(1)
|
BB Biotech AG
|
Ionis Pharmaceuticals, Inc.
|
5.6%(1)
|
Ionis Pharmaceuticals, Inc.
|
Isis USA Limited
|
100%
|
Ionis Pharmaceuticals, Inc.
|
PerIsis I Development Corporation
|
100%
|
Ionis Pharmaceuticals, Inc.
|
Symphony GenIsis, Inc.
|
100%
|
Ionis Pharmaceuticals, Inc.
|
Akcea Therapeutics, Inc.
|
100%
|
(1)
|
Based on most recent filings with the SEC
|